The report highlights the company's commitment to sustainable development, including its economic, social and environmental performance. The report also outlines the company's focus on transparency and ethical business practices, including its anti-corruption measures, and its commitment to providing affordable access to medicines for patients in Romania and around the world. Specific highlights from 2018 include the inauguration of the company's fourth representative office in Ukraine, the expansion of the company's product portfolio to over 158 products, the company's continued commitment to investing in research and development of new medicines, and the company's ongoing efforts to promote the judicious use of antibiotics through its ""Antibiotics of the Third Millennium"" program.
